<DOC>
	<DOC>NCT01755507</DOC>
	<brief_summary>Evaluation of the efficacy of different doses of nor UDCA vs. placebo for the treatment of Primary Sclerosing Cholangitis (PSC). Identification of optimal dose(s)for the treatment of PSC.</brief_summary>
	<brief_title>Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis</brief_title>
	<detailed_description>Double-blind, randomized, multi-center, placebo-controlled, comparative exploratory phase II-finding trial.The study will be conducted with four treatment groups in the form of a parallel-group comparison and will serve to compare oral treatment with either 500 mg/d, 1000 mg/d or 1500 mg/d norursodeoxycholic acid capsules vs. Placebo capsules for the treatment of PSC.</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis, Sclerosing</mesh_term>
	<criteria>1. Signed Informed Consent 2. Verified diagnosis of PSC 3. PSC patients with or without IBD 4. Women of childbearing potential have to apply during the entire duration of the study a highly effective method of birth control. 1. History or presence of other concomitant liver diseases 2. Treatment with UDCA within 8 weeks prior to baseline visit. 3. Child B/C liver cirrhosis 4. Total bilirubin &gt; 3.0 mg/dl at screening or baseline. 5. Any relevant systemic disease 6. TSH&gt;ULN at screening 7. any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder 8. Any active malignant disease 9. Known intolerance/hypersensitivity to study drug 10. Existing or intended pregnancy of brest feeding 11. Simultaneous participation in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PSC</keyword>
</DOC>